Thomas Powles1, Jonathan E Rosenberg1, Guru P Sonpavde1, Yohann Loriot1, Ignacio Durán1, Jae-Lyun Lee1, Nobuaki Matsubara1, Christof Vulsteke1, Daniel Castellano1, Chunzhang Wu1, Mary Campbell1, Maria Matsangou1, Daniel P Petrylak1. 1. From Barts Cancer Centre, Queen Mary University of London, London (T.P.); Memorial Sloan Kettering Cancer Center, New York (J.E.R.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (G.P.S.); Gustave Roussy, Université Paris-Saclay, Villejuif, France (Y.L.); Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla, Cantabria (I.D.), and Hospital Universitario 12 de Octubre, Madrid (D.C.) - both in Spain; Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); National Cancer Center Hospital East, Chiba, Japan (N.M.); the Center for Oncological Research, University of Antwerp, Integrated Cancer Center Ghent, Ghent, Belgium (C.V.); Astellas Pharma, Northbrook, IL (C.W., M.M.); Seagen, Bothell, WA (M.C.); and Smilow Cancer Center, Yale School of Medicine, New Haven, CT (D.P.P.).
Abstract
BACKGROUND: Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. METHODS: We conducted a global, open-label, phase 3 trial of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-containing chemotherapy and had had disease progression during or after treatment with a PD-1 or PD-L1 inhibitor. Patients were randomly assigned in a 1:1 ratio to receive enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight on days 1, 8, and 15 of a 28-day cycle) or investigator-chosen chemotherapy (standard docetaxel, paclitaxel, or vinflunine), administered on day 1 of a 21-day cycle. The primary end point was overall survival. RESULTS: A total of 608 patients underwent randomization; 301 were assigned to receive enfortumab vedotin and 307 to receive chemotherapy. As of July 15, 2020, a total of 301 deaths had occurred (134 in the enfortumab vedotin group and 167 in the chemotherapy group). At the prespecified interim analysis, the median follow-up was 11.1 months. Overall survival was longer in the enfortumab vedotin group than in the chemotherapy group (median overall survival, 12.88 vs. 8.97 months; hazard ratio for death, 0.70; 95% confidence interval [CI], 0.56 to 0.89; P = 0.001). Progression-free survival was also longer in the enfortumab vedotin group than in the chemotherapy group (median progression-free survival, 5.55 vs. 3.71 months; hazard ratio for progression or death, 0.62; 95% CI, 0.51 to 0.75; P<0.001). The incidence of treatment-related adverse events was similar in the two groups (93.9% in the enfortumab vedotin group and 91.8% in the chemotherapy group); the incidence of events of grade 3 or higher was also similar in the two groups (51.4% and 49.8%, respectively). CONCLUSIONS: Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor. (Funded by Astellas Pharma US and Seagen; EV-301 ClinicalTrials.gov number, NCT03474107.).
BACKGROUND: Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. METHODS: We conducted a global, open-label, phase 3 trial of enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-containing chemotherapy and had had disease progression during or after treatment with a PD-1 or PD-L1 inhibitor. Patients were randomly assigned in a 1:1 ratio to receive enfortumab vedotin (at a dose of 1.25 mg per kilogram of body weight on days 1, 8, and 15 of a 28-day cycle) or investigator-chosen chemotherapy (standard docetaxel, paclitaxel, or vinflunine), administered on day 1 of a 21-day cycle. The primary end point was overall survival. RESULTS: A total of 608 patients underwent randomization; 301 were assigned to receive enfortumab vedotin and 307 to receive chemotherapy. As of July 15, 2020, a total of 301 deaths had occurred (134 in the enfortumab vedotin group and 167 in the chemotherapy group). At the prespecified interim analysis, the median follow-up was 11.1 months. Overall survival was longer in the enfortumab vedotin group than in the chemotherapy group (median overall survival, 12.88 vs. 8.97 months; hazard ratio for death, 0.70; 95% confidence interval [CI], 0.56 to 0.89; P = 0.001). Progression-free survival was also longer in the enfortumab vedotin group than in the chemotherapy group (median progression-free survival, 5.55 vs. 3.71 months; hazard ratio for progression or death, 0.62; 95% CI, 0.51 to 0.75; P<0.001). The incidence of treatment-related adverse events was similar in the two groups (93.9% in the enfortumab vedotin group and 91.8% in the chemotherapy group); the incidence of events of grade 3 or higher was also similar in the two groups (51.4% and 49.8%, respectively). CONCLUSIONS: Enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor. (Funded by Astellas Pharma US and Seagen; EV-301 ClinicalTrials.gov number, NCT03474107.).
Authors: J Bellmunt; R Fougeray; J E Rosenberg; H von der Maase; F A Schutz; Y Salhi; S Culine; T K Choueiri Journal: Ann Oncol Date: 2013-02-17 Impact factor: 32.976
Authors: Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud Journal: Lancet Date: 2017-12-18 Impact factor: 79.321
Authors: Peter C Black; Nimira S Alimohamed; David Berman; Normand Blais; Bernhard Eigl; Pierre I Karakiewicz; Wassim Kassouf; Girish S Kulkarni; Michael Ong; Alan Spatz; Srikala S Sridhar; Tracy Stockley; Theodorus van der Kwast; Huong Hew; Laura Park-Wyllie; Scott A North Journal: Can Urol Assoc J Date: 2020-03-23 Impact factor: 1.862
Authors: Thomas Powles; Se Hoon Park; Eric Voog; Claudia Caserta; Begoña P Valderrama; Howard Gurney; Haralabos Kalofonos; Siniša Radulović; Wim Demey; Anders Ullén; Yohann Loriot; Srikala S Sridhar; Norihiko Tsuchiya; Evgeny Kopyltsov; Cora N Sternberg; Joaquim Bellmunt; Jeanny B Aragon-Ching; Daniel P Petrylak; Robert Laliberte; Jing Wang; Bo Huang; Craig Davis; Camilla Fowst; Nuno Costa; John A Blake-Haskins; Alessandra di Pietro; Petros Grivas Journal: N Engl J Med Date: 2020-09-18 Impact factor: 91.245
Authors: Srikala S Sridhar; Normand Blais; Ben Tran; M Neil Reaume; Scott A North; Martin R Stockler; Kim N Chi; Neil E Fleshner; Geoffrey Liu; John W Robinson; Som D Mukherjee; Yasmin Rahim; Eric Winquist; Christopher M Booth; Nghia Trung Nguyen; Emma K Beardsley; Nimira S Alimohamed; Gail T McDonald; Keyue Ding; Wendy R Parulekar Journal: JAMA Oncol Date: 2020-11-01 Impact factor: 31.777
Authors: Jonathan Rosenberg; Srikala S Sridhar; Jingsong Zhang; David Smith; Dean Ruether; Thomas W Flaig; Joaquina Baranda; Joshua Lang; Elizabeth R Plimack; Randeep Sangha; Elisabeth I Heath; Jamie Merchan; David I Quinn; Sandy Srinivas; Matthew Milowsky; Chunzhang Wu; Elaina M Gartner; Peiying Zuo; Amal Melhem-Bertrandt; Daniel P Petrylak Journal: J Clin Oncol Date: 2020-02-07 Impact factor: 44.544
Authors: Marco Stellato; Daniele Santini; Maria Concetta Cursano; Simone Foderaro; Giuseppe Tonini; Giuseppe Procopio Journal: J Bone Oncol Date: 2021-11-28 Impact factor: 4.072
Authors: Chana Weinstock; Matthew D Galsky; Elaine Chang; Andrea B Apolo; Rick Bangs; Stephanie Chisolm; Vinay Duddalwar; Jason A Efstathiou; Kirsten B Goldberg; Donna E Hansel; Ashish M Kamat; Paul G Kluetz; Seth P Lerner; Elizabeth Plimack; Tatiana Prowell; Harpreet Singh; Daniel Suzman; Evan Y Yu; Hui Zhang; Julia A Beaver; Richard Pazdur Journal: Nat Rev Urol Date: 2021-09-10 Impact factor: 14.432